Octreotide in the treatment of severe chemotherapy-induced diarrhea

作者: J. Zidan , N. Haim , A. Beny , M. Stein , E. Gez

DOI: 10.1023/A:1008372228462

关键词:

摘要: Summary Background: Chemotherapy-induced diarrhea (CID) is a common side effect of number chemotherapeu tic agents. Conventional therapy for severe CID with opioids or loperamide moderately effective. A prospective trial was conducted using octreotide acetate treatment refractory to loperamide. Patients and methods: Thirty-two patients grade 2 3 were treated at dosage 100 ug subcutaneousl y 3x/day three days followed by 50 days. Previous chemotherapy consisted regimens containing fluorouracil, leucovorin, CPT-11, cyclophosphamide, methotrexate cisplatin. Primary tumors colorectal (n = 23), gastric 3), other cancers 6). Results: Complete resolution obtained in 30 32 (94%); 5 within 24 hours, 14 48 11 72 hours treatment. Nineteen as outpatients. Thirteen hospitalized median Response unaffected age, gender, performance status, previous primary tumor site. No effects related observed. Conclusions: Octreotide an effective, safe given primarily second-line after failure.

参考文章(17)
M L Rothenberg, J R Eckardt, J G Kuhn, H A Burris, J Nelson, S G Hilsenbeck, G I Rodriguez, A M Thurman, L S Smith, S G Eckhardt, G R Weiss, G L Elfring, D A Rinaldi, L J Schaaf, D D Von Hoff, Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Journal of Clinical Oncology. ,vol. 14, pp. 1128- 1135 ,(1996) , 10.1200/JCO.1996.14.4.1128
S Wadler, H Haynes, P H Wiernik, Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. Journal of Clinical Oncology. ,vol. 13, pp. 222- 226 ,(1995) , 10.1200/JCO.1995.13.1.222
J A Conti, N E Kemeny, L B Saltz, Y Huang, W P Tong, T C Chou, M Sun, S Pulliam, C Gonzalez, Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. Journal of Clinical Oncology. ,vol. 14, pp. 709- 715 ,(1996) , 10.1200/JCO.1996.14.3.709
Maria I. Dueno, Julio C. Bai, William C. Santangelo, Guenter J. Krejs, Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel Digestive Diseases and Sciences. ,vol. 32, pp. 1092- 1096 ,(1987) , 10.1007/BF01300194
Mark Donowitz, Joan Wicks, Geoffrey W. G. Sharp, Drug Therapy for Diarrheal Diseases: A Look Ahead Clinical Infectious Diseases. ,vol. 8, pp. 188- 201 ,(1986) , 10.1093/CLINIDS/8.SUPPLEMENT_2.S188
B. Lembcke, W. Creutzfeldt, S. Schleser, R. Ebert, C. Shaw, I. Koop, Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion. ,vol. 36, pp. 108- 124 ,(1987) , 10.1159/000199408
D.B.W. de Roy van Zuidewijn, P.H.M. Schillings, Th. Wobbes, Th. Hendriks, H.H.M. de Boer, Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats Experimental and Molecular Pathology. ,vol. 56, pp. 96- 107 ,(1992) , 10.1016/0014-4800(92)90027-9
Stefano Casinu, Anna Fedeli, Stefano Luzi Fedeli, Giuseppina Catalano, Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil European Journal of Cancer. ,vol. 28, pp. 482- 483 ,(1992) , 10.1016/S0959-8049(05)80082-6
Gary M. Dosik, Mario Luna, Manuel Valdivieso, Kenneth B. McCredie, Edmund A. Gehan, Blas Gil-Extremera, Terry L. Smith, Gerald P. Bodey, Necrotizing colitis in patients with cancer The American Journal of Medicine. ,vol. 67, pp. 646- 656 ,(1979) , 10.1016/0002-9343(79)90248-1